| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| R&D Expense | $6.4M | — | -24.5% |
| SG&A Expense | $5.1M | — | +27.3% |
| Operating Income | -$11.5M | — | -13.4% |
| Net Income | -$24.2M | — | -127.9% |
| EPS (Basic) | -$1.25 | — | +0.0% |
| EPS (Diluted) | -$1.25 | — | +0.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $15.0M | +196.4% | -26.0% |
| Current Assets | $16.6M | +140.2% | -33.0% |
| Total Assets | $29.7M | +48.7% | -24.5% |
| Current Liabilities | $15.0M | +6.4% | -25.6% |
| Total Liabilities | $17.0M | +17.1% | -63.0% |
| Stockholders' Equity | $12.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$9.0M | — | -24.1% |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | $18.9M | — | +151.3% |
| +292.3% |